Bellerophon Therapeutics | 15-12G: Notice of termination of registration of a class of securities under Section 12(g) (and amendment thereto)
Mar 6 11:34 ET
Bellerophon Therapeutics | 8-K: Current report
Mar 4 17:55 ET
Bellerophon Therapeutics | SCHEDULE 13G: Others
Mar 1 10:09 ET
Bellerophon Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Perceptive Advisors LLC(0.0%),Joseph Edelman(0.0%), etc.
Feb 14 16:55 ET
Bellerophon Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-TANG CAPITAL PARTNERS, LP(0.0%),Tang Capital Management, LLC(0.0%), etc.
Feb 14 16:03 ET
Bellerophon Therapeutics | DEFA14A: Others
Feb 12 15:50 ET
Bellerophon Therapeutics | DEFA14A: Others
Feb 12 12:40 ET
Bellerophon Therapeutics | 8-K: Current report
Jan 30 09:32 ET
Bellerophon Therapeutics | SCHEDULE 13G: Others
Jan 26 14:35 ET
Bellerophon Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-507 Summit LLC(8.4%),Lepercq Capital Management LLC(8.4%), etc.
Jan 26 10:49 ET
Bellerophon Therapeutics | 8-K: Current report
Jan 22 00:00 ET
Bellerophon Therapeutics | 8-K: Current report
Jan 10 00:00 ET
Bellerophon Therapeutics | DEFA14A: Others
Jan 3 00:00 ET
Bellerophon Therapeutics | 25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities (and amendment thereto)
Dec 27, 2023 00:00 ET
Bellerophon Therapeutics | 8-K: Current report
Dec 12, 2023 16:10 ET
Bellerophon Therapeutics | 8-K: Current report
Nov 21, 2023 16:05 ET
Bellerophon Therapeutics: Q3 2023 Earnings Report
Nov 14, 2023 16:31 ET
Bellerophon Therapeutics | DEF 14A: Definitive information statements
Nov 6, 2023 16:30 ET
Bellerophon Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Oct 27, 2023 10:50 ET
Bellerophon Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Theodore Wang(0.5%),Puissance Life Science Opportunities Fund VI(0%), etc.
Oct 17, 2023 21:05 ET
No Data
No Data